

Steven Morgan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5998345/publications.pdf>

Version: 2024-02-01

55
papers

1,960
citations

279798

23
h-index

254184

43
g-index

55
all docs

55
docs citations

55
times ranked

2986
citing authors

#	ARTICLE	IF	CITATIONS
1	Adherence at 2 years with distribution of essential medicines at no charge: The CLEAN Meds randomized clinical trial. PLoS Medicine, 2021, 18, e1003590.	8.4	9
2	Effect on Treatment Adherence of Distributing Essential Medicines at No Charge. JAMA Internal Medicine, 2020, 180, 27.	5.1	41
3	Variation in the prescription drugs covered by health systems across high-income countries: A review of and recommendations for the academic literature. Health Policy, 2020, 124, 231-238.	3.0	1
4	New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. BMJ, The, 2020, 368, l4408.	6.0	20
5	Failure to follow medication changes made at hospital discharge is associated with adverse events in 30 days. Health Services Research, 2020, 55, 512-523.	2.0	15
6	Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ, The, 2020, 368, l4627.	6.0	68
7	Both New and Chronic Potentially Inappropriate Medications Continued at Hospital Discharge Are Associated With Increased Risk of Adverse Events. Journal of the American Geriatrics Society, 2020, 68, 1184-1192.	2.6	38
8	Challenges at Care Transitions: Failure to Follow Medication Changes Made at Hospital Discharge. American Journal of Medicine, 2019, 132, 1216-1224.e5.	1.5	11
9	Patterns of borrowing to finance out-of-pocket prescription drug costs in Canada: a descriptive analysis. CMAJ Open, 2018, 6, E544-E550.	2.4	3
10	How to pay for national pharmacare. Cmaj, 2018, 190, E1384-E1388.	2.0	2
11	Prescription drug coverage in Canada: a review of the economic, policy and political considerations for universal pharmacare. Journal of Pharmaceutical Policy and Practice, 2018, 11, 28.	2.4	47
12	An analysis of expenditures on primary care prescription drugs in the United States versus ten comparable countries. Health Policy, 2018, 122, 1012-1017.	3.0	6
13	New generic pricing scheme maintains high prices and risks of shortages. Cmaj, 2018, 190, E410-E411.	2.0	5
14	The consequences of patient charges for prescription drugs in Canada: a cross-sectional survey. CMAJ Open, 2018, 6, E63-E70.	2.4	57
15	Payers's experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia. Health Policy, 2017, 121, 354-362.	3.0	67
16	Estimated effects of adding universal public coverage of an essential medicines list to existing public drug plans in Canada. Cmaj, 2017, 189, E295-E302.	2.0	24
17	A rapidly changing global medicines environment: How adaptable are funding decision-making systems?. Health Policy, 2017, 121, 637-643.	3.0	6
18	The effects of catastrophic drug plan deductibles on older women's use of cardiovascular medicines: a retrospective cohort study. CMAJ Open, 2017, 5, E198-E204.	2.4	5

#	ARTICLE	IF	CITATIONS
19	Long-term sedative use among community-dwelling adults: a population-based analysis. <i>CMAJ Open</i> , 2017, 5, E52-E60.	2.4	19
20	Patterns, predictors and persistence of chronic sedative use: a population-based observational study of older adults in British Columbia, Canada. <i>European Journal of Clinical Pharmacology</i> , 2017, 73, 1001-1008.	1.9	6
21	Protocol for a randomised controlled trial evaluating the effects of providing essential medicines at no charge: the Carefully seLected and Easily Accessible at No Charge Medicines (CLEAN Meds) trial. <i>BMJ Open</i> , 2017, 7, e015686.	1.9	7
22	Drivers of expenditure on primary care prescription drugs in 10 high-income countries with universal health coverage. <i>Cmaj</i> , 2017, 189, E794-E799.	2.0	36
23	High-Cost Users of Prescription Drugs: A Population-Based Analysis from British Columbia, Canada. <i>Health Services Research</i> , 2017, 52, 697-719.	2.0	13
24	Evaluating the effects of Quebec's private-public drug insurance system. <i>Cmaj</i> , 2017, 189, E1259-E1263.	2.0	14
25	Understanding the patient experience of cost-related non-adherence to prescription medications through typology development and application. <i>Social Science and Medicine</i> , 2017, 194, 51-59.	3.8	30
26	Cost-related non-adherence to prescribed medicines among older adults: a cross-sectional analysis of a survey in 11 developed countries. <i>BMJ Open</i> , 2017, 7, e014287.	1.9	82
27	Essential medicines for universal health coverage. <i>Lancet, The</i> , 2017, 389, 403-476.	13.7	366
28	The cost of entry: An analysis of pharmaceutical registration fees in low-, middle-, and high-income countries. <i>PLoS ONE</i> , 2017, 12, e0182742.	2.5	8
29	The impact of a physician detailing and sampling program for generic atorvastatin: an interrupted time series analysis. <i>Implementation Science</i> , 2017, 12, 141.	6.9	2
30	Patterns and trends in long-term opioid use for non-cancer pain in British Columbia, 2005-2012. <i>Canadian Journal of Public Health</i> , 2016, 107, e404-e409.	2.3	16
31	Postpartum domperidone use in British Columbia: a retrospective cohort study. <i>CMAJ Open</i> , 2016, 4, E13-E19.	2.4	25
32	Determinants of trends in prescription opioid use in British Columbia, Canada, 2005-2013. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 553-559.	1.9	23
33	The association between domperidone and ventricular arrhythmia in the postpartum period. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 1210-1214.	1.9	25
34	Postpartum Hemorrhage and Use of Serotonin Reuptake Inhibitor Antidepressants in Pregnancy. <i>Obstetrics and Gynecology</i> , 2016, 127, 553-561.	2.4	37
35	Frequency and cost of potentially inappropriate prescribing for older adults: a cross-sectional study. <i>CMAJ Open</i> , 2016, 4, E346-E351.	2.4	88
36	Sex differences in the risk of receiving potentially inappropriate prescriptions among older adults. <i>Age and Ageing</i> , 2016, 45, 535-542.	1.6	60

#	ARTICLE	IF	CITATIONS
37	Toward better prescription drug surveillance in Canada. <i>Cmaj</i> , 2016, 188, E252-E253.	2.0	5
38	Universal prescription drug coverage in Canada. <i>Healthcare Management Forum</i> , 2016, 29, 247-254.	1.4	43
39	Sensitivity and specificity of administrative mortality data for identifying prescription opioid-related deaths. <i>Cmaj</i> , 2016, 188, E67-E72.	2.0	19
40	Trends and sex differences in prescription opioid deaths in British Columbia, Canada. <i>Injury Prevention</i> , 2016, 22, 288-290.	2.4	21
41	Postmarket policy considerations for biosimilar oncology drugs. <i>Lancet Oncology</i> , The, 2016, 17, e31-e38.	10.7	55
42	A Better Prescription: Advice for a National Strategy on Pharmaceutical Policy in Canada. <i>Healthcare Policy</i> , 2016, 12, 18-36.	0.6	12
43	Estimated cost of universal public coverage of prescription drugs in Canada. <i>Cmaj</i> , 2015, 187, 491-497.	2.0	73
44	Sex Disparities in Post-Acute Myocardial Infarction Pharmacologic Treatment Initiation and Adherence. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 586-592.	2.2	47
45	A drug by any other name generic and brand-name drugs are clinically equivalent. <i>Journal of Primary Health Care</i> , 2015, 7, 93.	0.6	0
46	Inter-jurisdictional cooperation on pharmaceutical product listing agreements: views from Canadian provinces. <i>BMC Health Services Research</i> , 2013, 13, 34.	2.2	9
47	International Best Practices For Negotiating "Reimbursement Contracts" With Price Rebates From Pharmaceutical Companies. <i>Health Affairs</i> , 2013, 32, 771-777.	5.2	32
48	Canadian policy makers' views on pharmaceutical reimbursement contracts involving confidential discounts from drug manufacturers. <i>Health Policy</i> , 2013, 112, 248-254.	3.0	18
49	Use of product listing agreements by Canadian provincial drug benefit plans. <i>Healthcare Policy</i> , 2013, 8, 45-55.	0.6	10
50	The effect of cost on adherence to prescription medications in Canada. <i>Cmaj</i> , 2012, 184, 297-302.	2.0	182
51	Canadian pharmacare: looking back, looking forward. <i>Healthcare Policy</i> , 2012, 8, 14-23.	0.6	11
52	Ethnic differences in the use of prescription drugs: a cross-sectional analysis of linked survey and administrative data. <i>Open Medicine</i> , 2011, 5, e87-93.	1.5	14
53	"Breakthrough" drugs and growth in expenditure on prescription drugs in Canada. <i>BMJ: British Medical Journal</i> , 2005, 331, 815-816.	2.3	82
54	Seniors' prescription drug cost inflation and cost containment: evidence from British Columbia. <i>Health Policy</i> , 2004, 68, 299-307.	3.0	26

#	ARTICLE	IF	CITATIONS
55	The economics of direct-to-consumer advertising of prescription-only drugs: prescribed to improve consumer welfare?. <i>Journal of Health Services Research and Policy</i> , 2003, 8, 237-244.	1.7	19